Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients

Martina Guthoff, Kilian Berger, Karina Althaus, Thomas Mühlbacher, Tamam Bakchoul, Wolfgang Steurer, Silvio Nadalin, Alfred Königsrainer & Nils Heyne
Background: Induction therapy is crucial in kidney transplantation and constitutes an important cornerstone for long-term allograft survival. Alemtuzumab is a depleting CD52-specific antibody with T and B cell activity, leading to prolonged lymphocyte depletion for up to 12 months, with profound immunosuppression and an associated risk of serious infections. Current concepts aim to optimize dosing strategies to reduce side effects. Here we present data from an ongoing centre protocol consisting of low-dose alemtuzumab induction and...
46 views reported since publication in 2020.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
9 downloads reported since publication in 2020.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?